As killer virus outbreaks hit unprecedented levels, nonprofit hands $37.5M to Themis to tackle Lassa/MERS vaccines
A nonprofit formed in the aftermath of the recent Ebola outbreak is handing an Austrian biotech $37.5 million to put two killer diseases on its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
